Phaseline

Targets › PSCA

PSCA (Prostate stem cell antigen): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 7 Phase 1; Oncology; next expected readout Mar 2027.

May be involved in the regulation of cell proliferation. Has a cell-proliferation inhibition activity in vitro..; FUNCTION: May act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. (UniProt, O43653)

Open in Phaseline: the race on PSCA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing BiotechETB-DualNK-01
Dual-target anti-PSMA/PSCA CAR-NK cells
PSMA, PSCAPhase 1Metastatic Castration-resistant Prostate CancerMar 2027
City of Hope Medical CenterAutologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Anti-PSCA CAR-T cell therapy targeting PSCA+ tumor cells
PSCAPhase 1Castration-Resistant Prostate CarcinomaMar 2027
AmgenAMG 509
PSCA-directed chimeric costimulatory receptor T cell therapy
PSCAPhase 1Extensive Stage Small Cell Lung Cancer; Prostate Cancer; Small Cell Lung CancerMar 2028
Regeneron PharmaceuticalsBPX-601
Anti-PSCA CAR-T cell therapy
PSCAPhase 1Prostate CancerFeb 2030

Conditions

Prostate Cancer (2) Castration-Resistant Prostate Carcinoma (2) Extensive Stage Small Cell Lung Cancer (1) Small Cell Lung Cancer (1) Metastatic Castration-resistant Prostate Cancer (1)

Modalities

mixed (3), other (1)

Companies

Amgen (1) City of Hope Medical Center (1) Regeneron Pharmaceuticals (1) Beijing Biotech (1)

Related targets

PSMA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.